Affibody molecules as engineered protein drugs

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · see citing works

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works

Serum Albumin

Peters, T. (1985) · Advances in protein chemistry · doi:10.1016/s0065-3233(08)60065-0 · Cited by 2,183 · see citing works

Cetuximab for the Treatment of Colorectal Cancer

Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · see citing works

Cetuximab in the treatment of colorectal cancer.

Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518 · see citing works

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503 · see citing works

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Hillmen, P., Young, N. S., Schubert, J. E. A., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,304 · see citing works

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 952 · see citing works

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G. B., Luger, T. A., Ohtsuki, M., Reich, K., Amato, D. A., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 851 · see citing works

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

Jones, S. A., Scheller, J., & Rose‐John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683 · see citing works

Engineering novel binding proteins from nonimmunoglobulin domains

Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676 · see citing works

Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry

Pauletti, G. M., Dandekar, S., Rong, H.-M., Ramos, L., Peng, H., Seshadri, R., & Slamon, D. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3651 · Cited by 670 · see citing works

Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain

Nord, K., Gunneriusson, E., Ringdahl, J., Ståhl, S., Uhlén, M., & Nygren, P. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-772 · Cited by 663 · see citing works

Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

Löfblom, J., Feldwisch, J., Максимилианович, Т. В., Carlsson, J., Ståhl, S., & Frejd, F. Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.014 · Cited by 653 · see citing works

Bispecific antibodies

Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 585 · see citing works

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 578 · see citing works

Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule

Orlova, A., Magnusson, M., Eriksson, T. L. J., Nilsson, M., Larsson, B., Höidén‐Guthenberg, I., Widström, C., Carlsson, J., Максимилианович, Т. В., Ståhl, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3521 · Cited by 570 · see citing works

A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)

Som, P., Atkins, H. L., Bandoypadhyay, D., Fowler, J. S., MacGregor, R. R., Matsui, K., OSTER, Z. H., Sacker, D. F., Shiue, C., Turner, H., et al. (1980) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198012000-00045 · Cited by 504 · see citing works

Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation

Hoyer, W., Grönwall, C., Jonsson, A., Ståhl, S., & Härd, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711731105 · Cited by 411 · see citing works

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · see citing works

Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use

Pastorek, J., & Pastoreková, S. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.08.002 · Cited by 331 · see citing works

Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules

Baum, R. P., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Максимилианович, Т. В., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073239 · Cited by 308 · see citing works

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [ 68 Ga]ABY-025 Affibody PET/CT

Sörensen, J., Velikyan, I., Sandberg, D., Wennborg, A., Feldwisch, J., Максимилианович, Т. В., Orlova, A., Sandström, M., Lubberink, M., Olofsson, H., et al. (2015) · Theranostics · doi:10.7150/thno.13502 · Cited by 264 · see citing works

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule

Sørensen, J., Sandberg, D., Sandström, M., Wennborg, A., Feldwisch, J., Максимилианович, Т. В., Åström, G., Lubberink, M., Garske‐Román, U., Carlsson, J., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131243 · Cited by 258 · see citing works

Engineering of a femtomolar affinity binding protein to human serum albumin

Jonsson, A., Dogan, J., Herne, N., Abrahmsén, L., & Nygren, P. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn028 · Cited by 243 · see citing works

Challenges and opportunities for non-antibody scaffold drugs

Vazquez-Lombardi, R., Phan, T. G., Zimmermann, C., Lowe, D., Jermutus, L., & Christ, D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.004 · Cited by 226 · see citing works

Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule

Максимилианович, Т. В., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sandström, M., Rosik, D., Carlsson, J., Lundqvist, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1630 · Cited by 221 · see citing works

Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer

Tugues, S., Koch, S., Gualandi, L., Li, X., & Claesson, L. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.004 · Cited by 206 · see citing works

Design of an Optimized Scaffold for Affibody Molecules

Feldwisch, J., Максимилианович, Т. В., Lendel, C., Herne, N., Sjöberg, A., Larsson, B., Rosik, D., Lindqvist, E., Fant, G., Höidén‐Guthenberg, I., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.002 · Cited by 182 · see citing works

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

Smolen, J. S., Burmester, G. R., Combe, B. G., Curtis, J. R., Hall, S., Haraoui, B. P., van Vollenhoven, R., Cioffi, C., Ecoffet, C., Gervitz, L. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31651-8 · Cited by 182 · see citing works

Directed Evolution to Low Nanomolar Affinity of a Tumor-Targeting Epidermal Growth Factor Receptor-Binding Affibody Molecule

Friedman, M., Orlova, A., Johansson, E., Eriksson, T. L. J., Höidén‐Guthenberg, I., Максимилианович, Т. В., Nilsson, F. Y., & Ståhl, S. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.12.060 · Cited by 173 · see citing works

Practical Theoretic Guidance for the Design of Tumor-Targeting Agents

Wittrup, K. D., Thurber, G. M., Schmidt, M. M., & Rhoden, J. J. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-396962-0.00010-0 · Cited by 172 · see citing works

The problem of choice: current biologic agents and future prospects in RA

Choy, E., Kavanaugh, A. F., & Jones, S. A. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.8 · Cited by 164 · see citing works

Amyloid‐ß‐directed immunotherapy for Alzheimer's disease

Lannfelt, L., Relkin, N. R., & Siemers, E. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12168 · Cited by 157 · see citing works

On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model

Orlova, A., Wållberg, H., Stone-Elander, S., & Tolmachev, V. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057919 · Cited by 152 · see citing works

Non-immunoglobulin based protein scaffolds

Löfblom, J., Frejd, F. Y., & Ståhl, S. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.002 · Cited by 147 · see citing works

Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides

Grönwall, C., Jonsson, A., Lindström, S., Gunneriusson, E., Ståhl, S., & Herne, N. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.09.013 · Cited by 127 · see citing works

Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount

Максимилианович, Т. В., Rosik, D., Wållberg, H., Sjöberg, A., Sandström, M., Hansson, M., Wennborg, A., & Orlova, A. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1283-x · Cited by 118 · see citing works

111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.

Максимилианович, Т. В., Nilsson, F. Y., Widström, C., Andersson, K., Rosik, D., Gedda, L., Wennborg, A., & Orlova, A. (2006) · PubMed · Cited by 111 · see citing works

Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients

Sandström, M., Lindskog, K., Velikyan, I., Wennborg, A., Feldwisch, J., Sandberg, D., Максимилианович, Т. В., Orlova, A., Sørensen, J., Carlsson, J., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.169342 · Cited by 111 · see citing works

Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy.

Nilsson, F. Y., & Tolmachev, V. (2007) · PubMed · Cited by 107 · see citing works

Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis

Badot, V., Galant, C., Toukap, A. N., Théate, I., Maudoux, A., den Eynde, B. J. V., Durez, P., Houssiau, F. A., & Lauwerys, B. R. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2678 · Cited by 99 · see citing works

Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold

Ahlgren, S., Orlova, A., Wållberg, H., Hansson, M., Sandström, M., Lewsley, R., Wennborg, A., Abrahmsén, L., Максимилианович, Т. В., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073346 · Cited by 97 · see citing works

PDGF Receptors in Tumor Biology: Prognostic and Predictive Potential

Paulsson, J., Ehnman, M., & Östman, A. (2014) · Future Oncology · doi:10.2217/fon.14.83 · Cited by 96 · see citing works

Commonly used tag combinations for tandem affinity purification

Li, Y. (2010) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090273 · Cited by 95 · see citing works

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

Silacci, M., Lembke, W., Woods, R., Attinger-Toller, I., Bänziger-Tobler, N. E., Batey, S., Santimaria, R., von der Bey, U., Koenig-Friedrich, S., Zha, W., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1093266 · Cited by 94 · see citing works

Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition

Максимилианович, Т. В., Tran, T. A., Rosik, D., Sjöberg, A., Abrahmsén, L., & Orlova, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.101527 · Cited by 93 · see citing works

Engineering of Affibody Molecules for Therapy and Diagnostics

Feldwisch, J., & Tolmachev, V. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_7 · Cited by 91 · see citing works

Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use

Samkoe, K. S., Gunn, J. R., Marra, K. A., Hull, S. M., Moodie, K. L., Feldwisch, J., Strong, T. V., Draney, D. R., Hoopes, P. J., Roberts, D. W., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1033-y · Cited by 87 · see citing works

Engineered High-Affinity Affibody Molecules Targeting Platelet-Derived Growth Factor Receptor β In Vivo

Lindborg, M., Cortez, E., Höidén‐Guthenberg, I., Gunneriusson, E., von Hage, E., Syud, F. A., Morrison, M., Abrahmsén, L., Herne, N., Pietras, K., et al. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.033 · Cited by 86 · see citing works

Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules

Kronqvist, N., Malm, M., Göstring, L., Gunneriusson, E., Nilsson, M., Höidén‐Guthenberg, I., Gedda, L., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq118 · Cited by 81 · see citing works

Sequestration of the Aβ Peptide Prevents Toxicity and Promotes Degradation In Vivo

Luheshi, L. M., Hoyer, W., de Barros, T. P., Härd, I. V. D., Brorsson, A., Macao, B., Persson, C., Crowther, D. C., Lomas, D. A., Ståhl, S., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000334 · Cited by 78 · see citing works

Affitoxin—A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors

Zieliński, R., Lyakhov, I. G., Jacobs, A., Chertov, O., Krämer-Marek, G., Francella, N., Stephen, A. G., Fisher, R. J., Blumenthal, R. P., & Capala, J. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ad4d5d · Cited by 72 · see citing works

Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification

Malm, M., Kronqvist, N., Lindberg, H., Gudmundsdotter, L., Bass, T. Z., Frejd, F. Y., Höidén‐Guthenberg, I., Varasteh, Z., Orlova, A., Максимилианович, Т. В., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062791 · Cited by 71 · see citing works

Suicide risk and psychiatric comorbidity in patients with psoriasis

Pompili, M., Innamorati, M., Trovarelli, S., Narcisi, A., Bellini, S., Orsini, D., Forte, A. M., Erbuto, D., Botti, E., Lamis, D. A., et al. (2016) · Journal of International Medical Research · doi:10.1177/0300060515593253 · Cited by 70 · see citing works

In Vivo Imaging of Xenograft Tumors Using an Epidermal Growth Factor Receptor-Specific Affibody Molecule Labeled with a Near-infrared Fluorophore

Gong, H., Kovar, J. L., Little, G., Chen, H., & Olive, D. M. (2010) · Neoplasia · doi:10.1593/neo.91446 · Cited by 68 · see citing works

Affibody-mediated PET imaging of HER3 expression in malignant tumours

Rosestedt, M., Andersson, K. G., Mitran, B., Максимилианович, Т. В., Löfblom, J., Orlova, A., & Ståhl, S. (2015) · Scientific Reports · doi:10.1038/srep15226 · Cited by 67 · see citing works

Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors

Honarvar, H., Westerlund, K., Altai, M., Sandström, M., Orlova, A., Максимилианович, Т. В., & Karlström, A. E. (2015) · Theranostics · doi:10.7150/thno.12766 · Cited by 67 · see citing works

Early Implementation of QbD in Biopharmaceutical Development: A Practical Example

Zurdo, J., Arnell, A., Obrezanova, O., Smith, N., de la Cuesta, R. G., Gallagher, T. R. A., Michael, R., Stallwood, Y., Ekblad, C., Abrahmsén, L., et al. (2015) · BioMed Research International · doi:10.1155/2015/605427 · Cited by 66 · see citing works

HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [99mTc(CO)3]+-Labeled Affibody Molecules

Hofström, C., Altai, M., Honarvar, H., Strand, J., Malmberg, J., Hosseinimehr, S. J., Orlova, A., Gräslund, T., & Максимилианович, Т. В. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400218y · Cited by 66 · see citing works

Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium

Ducreux, J., Durez, P., Galant, C., Nzeusseu-Toukap, A., den Eynde, B. V., Houssiau, F., & Lauwerys, B. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38202 · Cited by 65 · see citing works

Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody

Sexton, K. J., Tichauer, K. M., Samkoe, K. S., Gunn, J. R., Hoopes, P. J., & Pogue, B. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060390 · Cited by 63 · see citing works

Imaging of Platelet-Derived Growth Factor Receptor β Expression in Glioblastoma Xenografts Using Affibody Molecule111In-DOTA-Z09591

Максимилианович, Т. В., Varasteh, Z., Honarvar, H., Hosseinimehr, S. J., Eriksson, O., Jonasson, P., Frejd, F. Y., Abrahmsén, L., & Orlova, A. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.121814 · Cited by 62 · see citing works

Feasibility of Affibody-Based Bioorthogonal Chemistry–Mediated Radionuclide Pretargeting

Altai, M., Perols, A., Tsourma, M., Mitran, B., Honarvar, H., Robillard, M. S., Rossin, R., ten Hoeve, W., Lubberink, M., Orlova, A., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162248 · Cited by 62 · see citing works

Gallium-68-Labeled Affibody Molecule for PET Imaging of PDGFRβ Expression in Vivo

Strand, J., Varasteh, Z., Eriksson, O., Abrahmsén, L., Orlova, A., & Максимилианович, Т. В. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500284t · Cited by 61 · see citing works

Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules

Tolmachev, V., Mume, E., Sjöberg, S., Frejd, F., & Orlova, A. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1003-y · Cited by 61 · see citing works

Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule

Orlova, A., Malm, M., Rosestedt, M., Varasteh, Z., Andersson, K. G., Selvaraju, R., Altai, M., Honarvar, H., Strand, J., Ståhl, S., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2733-7 · Cited by 56 · see citing works

Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions

Ogata, A., & Tanaka, T. (2012) · International Journal of Rheumatology · doi:10.1155/2012/946048 · Cited by 54 · see citing works

Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis

Kanakaraj, P., Puffer, B. A., Yao, X.-T., Kankanala, S., Boyd, E., Shah, R. R., Wang, G., Patel, D., Krishnamurthy, R., Kaithamana, S., et al. (2012) · mAbs · doi:10.4161/mabs.21227 · Cited by 53 · see citing works

Cellular Effects of HER3-Specific Affibody Molecules

Göstring, L., Malm, M., Höidén‐Guthenberg, I., Frejd, F. Y., Ståhl, S., Löfblom, J., & Gedda, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040023 · Cited by 52 · see citing works

Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin‐binding domain allows for affinity purification and in vivo half‐life extension

Malm, M., Bass, T. Z., Gudmundsdotter, L., Lord, M., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2014) · Biotechnology Journal · doi:10.1002/biot.201400009 · Cited by 52 · see citing works

HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors

Zieliński, R., Lyakhov, I. G., Hassan, M., Kuban, M., Shafer-Weaver, K., Gandjbakhche, A., & Capala, J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2887 · Cited by 51 · see citing works

Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds

Malm, M., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2016) · mAbs · doi:10.1080/19420862.2016.1212147 · Cited by 49 · see citing works

Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides

LaFleur, D. W., Abramyan, D., Kanakaraj, P., Smith, R. G., Shah, R. R., Wang, G., Yao, X.-T., Kankanala, S., Boyd, E., Zaritskaya, L., et al. (2013) · mAbs · doi:10.4161/mabs.23043 · Cited by 48 · see citing works

Novel Exenatide Analogs with Peptidic Albumin Binding Domains: Potent Anti-Diabetic Agents with Extended Duration of Action

Levy, O. E., Jodka, C. M., Ren, S. S., Мамедова, Л. Т., Sharma, A., Samant, M. P., D’Souza, L. J., Soares, C. J., Yuskin, D., Jin, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087704 · Cited by 47 · see citing works

Simultaneous In Vivo Fluorescent Markers for Perfusion, Protoporphyrin Metabolism, and EGFR Expression for Optically Guided Identification of Orthotopic Glioma

Elliott, J. T., Marra, K. A., Evans, L. T., Davis, S. C., Samkoe, K. S., Feldwisch, J., Paulsen, K. D., Roberts, D. W., & Pogue, B. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1400 · Cited by 45 · see citing works

Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity

Fleetwood, F., Klint, S., Hanze, M., Gunneriusson, E., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2014) · Scientific Reports · doi:10.1038/srep07518 · Cited by 44 · see citing works

Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX

Garousi, J., Honarvar, H., Andersson, K. G., Mitran, B., Orlova, A., Buijs, J., Löfblom, J., Frejd, F. Y., & Максимилианович, Т. В. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00502 · Cited by 44 · see citing works

[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

Orlova, A., Hofström, C., Strand, J., Varasteh, Z., Sandström, M., Andersson, K., Максимилианович, Т. В., & Gräslund, T. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2284-8 · Cited by 43 · see citing works

Fusion of an albumin-binding domain extends the half-life of immunotoxins

Guo, R., Guo, W., Cao, L., Liu, H., Liu, J., Xu, H., Huang, W., Wang, F., & Hong, Z. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.07.046 · Cited by 43 · see citing works

Selection of affibody molecules to the ligand‐binding site of the insulin‐like growth factor‐1 receptor

Li, J., Lundberg, E. K., Vernet, E., Larsson, B., Höidén‐Guthenberg, I., & Gräslund, T. (2010) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090226 · Cited by 42 · see citing works

Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions

de Souza, A. L. R., Marra, K. A., Gunn, J. R., Samkoe, K. S., Hoopes, P. J., Feldwisch, J., Paulsen, K. D., & Pogue, B. W. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0980-7 · Cited by 42 · see citing works

A truncated and dimeric format of an Affibody library on bacteria enables FACS‐mediated isolation of amyloid‐beta aggregation inhibitors with subnanomolar affinity

Lindberg, H., Härd, T., Löfblom, J., & Ståhl, S. (2015) · Biotechnology Journal · doi:10.1002/biot.201500131 · Cited by 39 · see citing works

Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting

Westerlund, K., Honarvar, H., Максимилианович, Т. В., & Karlström, A. E. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00292 · Cited by 38 · see citing works

Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator

Andersson, K. G., Oroujeni, M., Garousi, J., Mitran, B., Ståhl, S., Orlova, A., Löfblom, J., & Максимилианович, Т. В. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3721 · Cited by 34 · see citing works

Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.

Gottlieb, A. B., Blauvelt, A., Prinz, J. C., Papanastasiou, P., Pathan, R. B., Nyirady, J., Fox, T., & Papavassilis, C. (2016) · PubMed · Cited by 32 · see citing works

Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin

Altai, M., Liu, H., Orlova, A., Максимилианович, Т. В., & Gräslund, T. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3614 · Cited by 28 · see citing works

An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo

Yu, F., Gudmundsdotter, L., Akal, A., Gunneriusson, E., Frejd, F. Y., & Nygren, P. (2014) · mAbs · doi:10.4161/mabs.36089 · Cited by 27 · see citing works

Evaluation of 99mTc-ZIGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression

Mitran, B., Altai, M., Hofström, C., Honarvar, H., Sandström, M., Orlova, A., Максимилианович, Т. В., & Gräslund, T. (2014) · Amino Acids · doi:10.1007/s00726-014-1859-z · Cited by 25 · see citing works

Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain

LIU, H., Seijsing, J., Frejd, F. Y., Максимилианович, Т. В., & Gräslund, T. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3027 · Cited by 24 · see citing works

Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.

Velikyan, I., Wennborg, A., Feldwisch, J., Lindman, H., Carlsson, J., & Sørensen, J. C. H. (2016) · PubMed Central · Cited by 23 · see citing works

Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling

Fleetwood, F., Güler, R., Gordon, E. J., Ståhl, S., Claesson, L., & Löfblom, J. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2088-7 · Cited by 22 · see citing works

Early treatment with eculizumab in atypical haemolytic uraemic syndrome

Garjau, M., Azancot, M. A., Ramos, R., Sánchez‐Corral, P., Montero, M. A., & Serón, D. (2012) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfr157 · Cited by 21 · see citing works

Staphylococcal display for combinatorial protein engineering of a head‐to‐tail affibody dimer binding the Alzheimer amyloid‐β peptide

Lindberg, H., Johansson, A., Härd, T., Ståhl, S., & Löfblom, J. (2012) · Biotechnology Journal · doi:10.1002/biot.201200228 · Cited by 16 · see citing works

A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies

Campa, M., & Menter, A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1237502 · Cited by 16 · see citing works

The clinical potential of Affibody-based inhibitors of C5 for therapeutic complement disruption

Berglund, M. M., & Strömberg, P. (2016) · Expert Review of Proteomics · doi:10.1586/14789450.2016.1148604 · Cited by 9 · see citing works

Design of protein-binding proteins from the target structure alone

Cao, L., Coventry, B., Goreshnik, I., Huang, B., Sheffler, W., Park, J. S., Jude, K. M., Marković, I., Kadam, R. U., Verschueren, K. H. G., et al. (2022) · Nature · doi:10.1038/s41586-022-04654-9 · Cited by 577 · see citing works

Molecular and functional imaging in cancer-targeted therapy: current applications and future directions

Bai, J., Qiu, S.-Q., & Zhang, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01366-y · Cited by 217 · see citing works

Electrochemical Impedance Spectroscopy Based Biosensors: Mechanistic Principles, Analytical Examples and Challenges towards Commercialization for Assays of Protein Cancer Biomarkers

Bertók, T., Lorencová, L., Chocholova, E., Jáné, E., Vikartovská, A., Kasák, P., & Tkáč, J. (2018) · ChemElectroChem · doi:10.1002/celc.201800848 · Cited by 180 · see citing works

Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics

Zorzi, A., Linciano, S., & Angelini, A. (2019) · MedChemComm · doi:10.1039/c9md00018f · Cited by 177 · see citing works

Engineered Protein Scaffolds as Next-Generation Therapeutics

Gebauer, M., & Skerra, A. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021118 · Cited by 164 · see citing works

The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics

Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 156 · see citing works

Nonenzymatic Stereoselective S -Glycosylation of Polypeptides and Proteins

Wan, L.-Q., Zhang, X., Zou, Y., Shi, R., Cao, J.-G., Xu, S., Deng, L., Zhou, L., Gong, Y., Shu, X., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c05156 · Cited by 131 · see citing works

The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart

Parisi, O. I., Francomano, F., Dattilo, M., Patitucci, F., Prete, S., Amone, F., & Puoci, F. (2022) · Journal of Functional Biomaterials · doi:10.3390/jfb13010012 · Cited by 134 · see citing works

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)

Kaufman, N. E. M., Dhingra, S., Jois, S. D. S., & Vicente, M. G. H. (2021) · Molecules · doi:10.3390/molecules26041076 · Cited by 134 · see citing works

Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications

Fu, R., Carroll, L. S., Yahioglu, G., Aboagye, E. O., & Miller, P. W. (2018) · ChemMedChem · doi:10.1002/cmdc.201800624 · Cited by 126 · see citing works

Photodynamic Therapy: Targeting Cancer Biomarkers for the Treatment of Cancers

Wang, X.-N., Luo, D., & Basilion, J. (2021) · Cancers · doi:10.3390/cancers13122992 · Cited by 108 · see citing works

Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape

Krueger, J. G., Frew, J. W., Jemec, G. B. E., Kimball, A. B., Kirby, B., Bechara, F. G., Navrazhina, K., Prens, E. P., Reich, K., Cullen, E., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad345 · Cited by 115 · see citing works

Current outlook on radionuclide delivery systems: from design consideration to translation into clinics

Peltek, O. O., Muslimov, A. R., Zyuzin, M. V., & Timin, A. S. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0524-9 · Cited by 109 · see citing works

Soluble ligands as drug targets

Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 110 · see citing works

Advances in psoriasis research: From pathogenesis to therapeutics

Sugumaran, D., Yong, A. C. H., & Stanslas, J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122991 · Cited by 108 · see citing works

From Whispering Gallery Mode Resonators to Biochemical Sensors

Loyez, M., Adolphson, M., Liao, J., & Yang, L. (2023) · ACS Sensors · doi:10.1021/acssensors.2c02876 · Cited by 107 · see citing works

Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer

Elshiaty, M., Schindler, H., & Christopoulos, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115632 · Cited by 98 · see citing works

Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?

Deonarain, M. P., Yahioglu, G., Stamati, I., Pomowski, A., Clarke, J., Edwards, B. M., Diez-Posada, S., & Stewart, A. (2018) · Antibodies · doi:10.3390/antib7020016 · Cited by 92 · see citing works

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

Islam, T., Hasan, M. M., Awal, A., Nurunnabi, M., & Ahammad, A. J. S. (2020) · Molecules · doi:10.3390/molecules25245787 · Cited by 89 · see citing works

Designer Oncolytic Adenovirus: Coming of Age

Baker, A. T., Hernandez, C. A., Halldén, G., & Parker, A. L. (2018) · Cancers · doi:10.3390/cancers10060201 · Cited by 84 · see citing works

Miniproteins as a Powerful Modality in Drug Development

Crook, Z. R., Nairn, N. W., & Olson, J. M. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.12.008 · Cited by 87 · see citing works

Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery

Richards, D. A. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.10.005 · Cited by 83 · see citing works

Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond

Garousi, J., Orlova, A., Frejd, F. Y., & Максимилианович, Т. В. (2020) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-020-00094-w · Cited by 73 · see citing works

Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy

Lindberg, J., Nilvebrant, J., Nygren, P., & Lehmann, F. (2021) · Molecules · doi:10.3390/molecules26196042 · Cited by 72 · see citing works

Protein scaffolds: antibody alternatives for cancer diagnosis and therapy

Luo, R., Liu, H., & Cheng, Z. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00094f · Cited by 71 · see citing works

Protein binders and their applications in developmental biology

Harmansa, S., & Affolter, M. (2018) · Development · doi:10.1242/dev.148874 · Cited by 69 · see citing works

Nanocarriers as Magic Bullets in the Treatment of Leukemia

Houshmand, M., Garello, F., Circosta, P., Stefanìa, R., Aime, S., Saglio, G. N., & Giachino, C. (2020) · Nanomaterials · doi:10.3390/nano10020276 · Cited by 63 · see citing works

Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy

Mohiuddin, T. M., Zhang, C., Sheng, W., Al-Rawe, M., Zeppernick, F. A., Meinhold-Heerlein, I. M., & Hussain, A. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032655 · Cited by 63 · see citing works

Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy

Zhang, M., Lam, K., & Xu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1207276 · Cited by 67 · see citing works

Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain

Chandler, P. G., & Buckle, A. M. (2020) · Cells · doi:10.3390/cells9030610 · Cited by 60 · see citing works

Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins

Tan, H., Su, W., Zhang, W., Wang, P., Sattler, M., & Zou, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190206105232 · Cited by 59 · see citing works

Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

Klint, S., Feldwisch, J., Gudmundsdotter, L., Bergstedt, K. D., Gunneriusson, E., Höidén‐Guthenberg, I., Wennborg, A., Nyborg, A. C., Kamboj, A. P., Peloso, P. M. J., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2209920 · Cited by 59 · see citing works

Development of light-responsive protein binding in the monobody non-immunoglobulin scaffold

Carrasco‐López, C., Zhao, E. M., Gil, A. A., Alam, N., Toettcher, J. E., & Avalos‬, J. L. (2020) · Nature Communications · doi:10.1038/s41467-020-17837-7 · Cited by 58 · see citing works

Improvement on Permeability of Cyclic Peptide/Peptidomimetic: Backbone N-Methylation as A Useful Tool

Li, Y., Li, W., & Xu, Z. (2021) · Marine Drugs · doi:10.3390/md19060311 · Cited by 57 · see citing works

Material-specific binding peptides empower sustainable innovations in plant health, biocatalysis, medicine and microplastic quantification

Mao, M., Ahrens, L., Luka, J., Contreras, F., Kurkina, T., Bienstein, M., Sárria, M. P., Schirinzi, G. F., Méhn, D., Valsesia, A., et al. (2024) · Chemical Society Reviews · doi:10.1039/d2cs00991a · Cited by 52 · see citing works

Post‐translational Assembly of Protein Parts into Complex Devices by Using SpyTag/SpyCatcher Protein Ligase

Sutherland, A. R., Alam, M. K., & Geyer, C. R. (2018) · ChemBioChem · doi:10.1002/cbic.201800538 · Cited by 53 · see citing works

Aligning physics and physiology: E ngineering antibodies for radionuclide delivery

Tsai, W. K., & Wu, A. M. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3622 · Cited by 50 · see citing works

Selection and characterization of a novel affibody peptide and its application in a two-site ELISA for the detection of cancer biomarker alpha-fetoprotein

Liu, J., Cui, D., Jiang, Y., Li, Y., Liu, Z., Tao, L., Zhao, Q. S., & Diao, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.10.245 · Cited by 49 · see citing works

Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics

Swenson, C., Mandava, G., Thomas, D. M., & Moellering, R. E. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00423 · Cited by 48 · see citing works

Modulation of virus-induced NF-κB signaling by NEMO coiled coil mimics

Sadek, J., Wuo, M. G., Rooklin, D. W., Hauenstein, A. V., Hong, S. H., Gautam, A. S., Wu, H., Zhang, Y., Cesarman, E., & Arora, P. S. (2020) · Nature Communications · doi:10.1038/s41467-020-15576-3 · Cited by 45 · see citing works

Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics

Zhong, X., & D’Antona, A. M. (2021) · Antibodies · doi:10.3390/antib10020013 · Cited by 45 · see citing works

Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers

Rawal, S. U., & Patel, M. M. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00630-6 · Cited by 45 · see citing works

Affibody-Indocyanine Green Based Contrast Agent for Photoacoustic and Fluorescence Molecular Imaging of B7–H3 Expression in Breast Cancer

Bam, R., Laffey, M., Nottberg, K., Lown, P. S., Hackel, B. J., & Wilson, K. E. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00239 · Cited by 42 · see citing works

Site-specific bioorthogonal protein labelling by tetrazine ligation using endogenous β-amino acid dienophiles

Richter, D., Laķis, E., & Piel, J. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01252-8 · Cited by 41 · see citing works

Application of Fluorescence-Guided Surgery to Subsurface Cancers Requiring Wide Local Excision

Samkoe, K. S., Bates, B. D., Elliott, J. T., LaRochelle, E. P. M., Gunn, J. R., Marra, K. A., Feldwisch, J., Ramkumar, D. B., Bauer, D. F., Paulsen, K. D., et al. (2018) · Cancer Control · doi:10.1177/1073274817752332 · Cited by 40 · see citing works

PLGA Nanoparticles Decorated with Anti-HER2 Affibody for Targeted Delivery and Photoinduced Cell Death

Shipunova, V. O., Sogomonyan, A. S., Zelepukin, I. V., Nikitin, M. P., & Deyev, S. M. (2021) · Molecules · doi:10.3390/molecules26133955 · Cited by 39 · see citing works

Review on Metal-Based Theranostic Nanoparticles for Cancer Therapy and Imaging

Fernandes, D. A. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231191493 · Cited by 44 · see citing works

Synthetic Control of Tertiary Helical Structures in Short Peptides

Wuo, M. G., Hong, S. H., Singh, A., & Arora, P. S. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10082 · Cited by 38 · see citing works

Protein-Catalyzed Capture Agents

Agnew, H. D., Coppock, M. B., Idso, M. N., Lai, B. T., Liang, J., McCarthy, A., Warren, C. M., & Heath, J. R. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00660 · Cited by 38 · see citing works

Affibody-Binding Ligands

Barozzi, A., Lavoie, R. A., Day, K. N., Prodromou, R., & Menegatti, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113769 · Cited by 37 · see citing works

Driving CARs with alternative navigation tools – the potential of engineered binding scaffolds

Zajc, C. U., Salzer, B., Taft, J. M., Reddy, S. T., Lehner, M., & Traxlmayr, M. W. (2020) · FEBS Journal · doi:10.1111/febs.15523 · Cited by 37 · see citing works

Palladium-Mediated Incorporation of Carboranes into Small Molecules, Peptides, and Proteins

Gazvoda, M., Dhanjee, H. H., Rodriguez, J., Brown, J. S., Farquhar, C. E., Truex, N. L., Loas, A., Buchwald, S. L., & Pentelute, B. L. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c01932 · Cited by 37 · see citing works

A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer

Jiang, P., Wang, L., Hou, B., Zhu, J., Zhou, M., Jiang, J., Wang, L., Chen, S., Zhu, S., Chen, J., et al. (2018) · Theranostics · doi:10.7150/thno.24607 · Cited by 36 · see citing works

Peptides and pseudopeptide ligands: a powerful toolbox for the affinity purification of current and next-generation biotherapeutics

Chu, W., Prodromou, R., Day, K. N., Schneible, J. D., Bacon, K. B., Bowen, J., Kilgore, R., Catella, C. M., Moore, B., Mabe, M. D., et al. (2020) · Journal of Chromatography A · doi:10.1016/j.chroma.2020.461632 · Cited by 36 · see citing works

Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69

Persson, J., Puuvuori, E., Zhang, B., Velikyan, I., Åberg, O., Müller, M., Nygren, P., Ståhl, S., Korsgren, O., Eriksson, O., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97694-6 · Cited by 34 · see citing works

Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer

Yamaguchi, H., Pantarat, N., Suzuki, T., & Evdokiou, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235835 · Cited by 34 · see citing works

Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection

Bam, R., Lown, P. S., Stern, L. A., Sharma, K., Wilson, K. E., Bean, G. R., Lutz, A. M., Paulmurugan, R., Hackel, B. J., Dahl, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1655 · Cited by 34 · see citing works

TARSyn: Tunable Antibiotic Resistance Devices Enabling Bacterial Synthetic Evolution and Protein Production

Rennig, M., Martínez, V., Mirzadeh, K., Dunås, F., Röjsäter, B., Daley, D. O., & Nørholm, M. H. H. (2017) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00200 · Cited by 33 · see citing works

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs

Altai, M., Leitao, C. D., Rinne, S. S., Vorobyeva, A., Atterby, C., Ståhl, S., Максимилианович, Т. В., Löfblom, J., & Orlova, A. (2018) · Cells · doi:10.3390/cells7100164 · Cited by 33 · see citing works

Engineering of binding functions into proteins

Gebauer, M., & Skerra, A. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.05.007 · Cited by 33 · see citing works

Recombinant immunotoxins development for HER2-based targeted cancer therapies

Mahmoudi, R., Dianat‐Moghadam, H., Poorebrahim, M., Siapoush, S., Poortahmasebi, V., Salahlou, R., & Rahmati, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02182-6 · Cited by 34 · see citing works

Recent advances in nanomaterials-based electrochemical immunosensors and aptasensors for HER2 assessment in breast cancer

Ahirwar, R. (2021) · Microchimica Acta · doi:10.1007/s00604-021-04963-2 · Cited by 33 · see citing works

Bispecific applications of non-immunoglobulin scaffold binders

Hober, S., Lindbo, S., & Nilvebrant, J. (2018) · Methods · doi:10.1016/j.ymeth.2018.09.010 · Cited by 32 · see citing works

PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients

Xu, Y., Wang, L., Pan, D., Yu, C., Mi, B., Huang, Q., Sheng, J., Yan, J., Wang, X., Yang, R., et al. (2019) · British Journal of Radiology · doi:10.1259/bjr.20190425 · Cited by 32 · see citing works

Development of active affibody aggregates induced by a self-assembling peptide for high sensitive detection of alpha-fetoprotein

Liu, J., Jiang, Y., Chen, X., Chen, L., Zhang, X., Cui, D., Li, Y., Liu, Z., Zhao, Q., & Diao, A. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135208 · Cited by 31 · see citing works

Directed evolution identifies high-affinity cystine-knot peptide agonists and antagonists of Wnt/β-catenin signaling

Hansen, S., Zhang, Y., Hwang, S., Nabhan, A. N., Li, W., Fuhrmann, J., Kschonsak, Y. T., Zhou, L., Nile, A. H., Gao, X., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2207327119 · Cited by 30 · see citing works

Antibodies as Biosensors’ Key Components: State-of-the-Art in Russia 2020–2021

Руденко, Н. В., Fursova, K. K., Shepelyakovskaya, A. O., Karatovskaya, A. P., & Brovko, F. A. (2021) · Sensors · doi:10.3390/s21227614 · Cited by 30 · see citing works

Fluorescence Molecular Targeting of Colon Cancer to Visualize the Invisible

Lwin, T. M., Turner, M. A., Amirfakhri, S., Nishino, H., Hoffman, R. M., & Bouvet, M. (2022) · Cells · doi:10.3390/cells11020249 · Cited by 30 · see citing works

Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma

Zhu, S., Chen, J., Xiong, Y., Kamara, S., Gu, M., Tang, W., Shao, C., Dong, H., Xue, X., Zheng, Z., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008223 · Cited by 29 · see citing works

Reactive oxygen species and enzyme dual-responsive biocompatible drug delivery system for targeted tumor therapy

Zhao, N., Ding, B., Zhang, Y., Klockow, J., Lau, K., Chin, F. T., Cheng, Z., & Liu, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.031 · Cited by 30 · see citing works

Targeted Two-Step Delivery of Oncotheranostic Nano-PLGA for HER2-Positive Tumor Imaging and Therapy In Vivo: Improved Effectiveness Compared to One-Step Strategy

Shipunova, V. O., Komedchikova, E. N., Kotelnikova, P. A., Nikitin, M. P., & Deyev, S. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030833 · Cited by 29 · see citing works

PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

Li, Q., Li, W., Xu, K., Xing, Y., Shi, H., Jing, Z., Li, S., & Hong, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041540 · Cited by 28 · see citing works

A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs

Morales, I. C., Dingfelder, F., Waibel, I., Turnbull, O. M., Patel, B., Cao, Z., Bjelke, J. R., Grell, S. N., Bennet, A., Hummer, A. M., et al. (2024) · mAbs · doi:10.1080/19420862.2024.2403156 · Cited by 27 · see citing works

Inhibition of Pore-Forming Proteins

Omersa, N., Podobnik, M., & Anderluh, G. (2019) · Toxins · doi:10.3390/toxins11090545 · Cited by 26 · see citing works

Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer

Alhuseinalkhudhur, A., Lubberink, M., Lindman, H., Максимилианович, Т. В., Frejd, F. Y., Feldwisch, J., Velikyan, I., & Sörensen, J. (2020) · EJNMMI Research · doi:10.1186/s13550-020-0603-9 · Cited by 25 · see citing works

Monobodies as tool biologics for accelerating target validation and druggable site discovery

Akkapeddi, P., Teng, K. W., & Koide, S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00188d · Cited by 23 · see citing works

Engineering Saccharomyces cerevisiae for the production and secretion of Affibody molecules

Gast, V., Sandegren, A., Dunås, F., Ekblad, S., Güler, R., Thorén, S., Mohedano, M. T., Molin, M., Engqvist, M. K. M., & Siewers, V. (2022) · Microbial Cell Factories · doi:10.1186/s12934-022-01761-0 · Cited by 25 · see citing works

Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency

Chen, C., Wakabayashi, T., Muraoka, M., Feng, S., Shan, C. W., Kun, C. C., Jang, C. T., Soehano, I., Shimizu, Y., Igawa, T., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1583996 · Cited by 23 · see citing works

Interactions Between Immunomodulatory Biomaterials and Immune Microenvironment: Cues for Immunomodulation Strategies in Tissue Repair

Chen, Y., Sun, W., Tang, H., Li, Y., Li, C., Wang, L., Chen, J., Lin, W., Li, S., Fan, Z., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.820940 · Cited by 24 · see citing works

Antibody-based Radiopharmaceuticals as Theranostic Agents: An Overview

Sharma, R., Suman, S. K., & Mukherjee, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220607160559 · Cited by 23 · see citing works

Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer

Yamaguchi, H., On, J., Morita, T., Suzuki, T., Okada, Y., Ono, J., & Evdokiou, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212213 · Cited by 22 · see citing works

Peptide ligands targeting the vesicular stomatitis virus G (VSV‐G) protein for the affinity purification of lentivirus particles

Barbieri, E., Mollica, G. N., Moore, B., Sripada, S. A., Shastry, S., Kilgore, R., Loudermilk, C. M., Whitacre, Z. H., Kilgour, K. M., Wüstenhagen, E., et al. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28594 · Cited by 22 · see citing works

Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule

Cai, H., Shi, Q., Tang, Y., Chen, L., Chen, Y., Tao, Z., Yang, H., Xie, F., Wu, X., Liu, N., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01317 · Cited by 22 · see citing works

Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR

Stiller, C., Viktorsson, K., Gomero, E. P., Hååg, P., Arapi, V., Kaminskyy, V. O., Kamali, C., Petris, L. D., Ekman, S., Lewensohn, R., et al. (2021) · Cancers · doi:10.3390/cancers13040922 · Cited by 21 · see citing works

Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients

Miao, H., Sun, Y., Jin, Y., Hu, X., Song, S., & Zhang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894767 · Cited by 21 · see citing works

Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor β

Wegrzyniak, O., Zhang, B., Rokka, J., Rosestedt, M., Mitran, B., Cheung, P., Puuvuori, E., Ingvast, S., Persson, J., Nordström, H., et al. (2023) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00210-6 · Cited by 21 · see citing works

Bispecific affibody molecule targeting HPV16 and HPV18E7 oncoproteins for enhanced molecular imaging of cervical cancer

Zhu, S., Zhu, J., Song, Y., Chen, J., Wang, L., Zhou, M., Jiang, P., Li, W., Xue, X., Zhao, K., et al. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9167-2 · Cited by 21 · see citing works

Adding a Twist to Lateral Flow Immunoassays: A Direct Replacement of Antibodies with Helical Affibodies, from Selection to Application

Sadler, C. J., Creamer, A., Giang, K. A., Darmawan, K. K., Shamsabadi, A., Richards, D. A., Nilvebrant, J., Wojciechowski, J. P., Charchar, P., Burdis, R., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17452 · Cited by 22 · see citing works

Molecular imaging for cancer immunotherapy

Lim, E., Drake, C., & Mintz, A. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.03.001 · Cited by 15 · see citing works

Outer membrane vesicles as versatile tools for therapeutic approaches

Zingl, F. G., Leitner, D. R., Thapa, H. B., & Schild, S. (2021) · microLife · doi:10.1093/femsml/uqab006 · Cited by 20 · see citing works

Structure–Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy

Biri‐Kovács, B., Adorján, A. E., Szabó, I., Szeder, B., Bősze, S. E., & Mező, G. (2020) · Biomolecules · doi:10.3390/biom10020183 · Cited by 20 · see citing works

Affimers as an alternative to antibodies for protein biomarker enrichment

Tans, R., van Rijswijck, D. M. H., Davidson, A., Hannam, R., Ricketts, B., Tack, C. J., Wessels, H. J. C. T., Gloerich, J., & van Gool, A. J. (2020) · Protein Expression and Purification · doi:10.1016/j.pep.2020.105677 · Cited by 20 · see citing works

A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies

Xia, L., Wu, Y. Y., Ren, Y., Wang, Z., Zhou, N., Zhou, W., Zhou, L., Jia, L., He, C., Meng, X., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186388 · Cited by 19 · see citing works

Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules

Garousi, J., Vorobyeva, A., & Altai, M. (2020) · Molecules · doi:10.3390/molecules25112673 · Cited by 19 · see citing works

Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles

Voltà‐Durán, E., Serna, N., Sánchez‐García, L., Aviñó, A. M., Sánchez, J. M., López‐Laguna, H., Cano‐Garrido, O., Casanova, I., Mangues, R., Eritja, R., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.11.018 · Cited by 19 · see citing works

Integrating Dynamic Network Analysis with AI for Enhanced Epitope Prediction in PD-L1:Affibody Interactions

Gomes, D. E. B., Yang, B., Vanella, R., Nash, M. A., & Bernardi, R. C. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c05869 · Cited by 18 · see citing works

Biophysical Characterization Platform Informs Protein Scaffold Evolvability

Golinski, A. W., Holec, P. V., Mischler, K. M., & Hackel, B. J. (2019) · ACS Combinatorial Science · doi:10.1021/acscombsci.8b00182 · Cited by 18 · see citing works

Protein A superantigen: structure, engineering and molecular basis of antibody recognition

Mazigi, O., Schofield, P., Langley, D. B., & Christ, D. (2019) · Protein Engineering Design and Selection · doi:10.1093/protein/gzz026 · Cited by 18 · see citing works

Long‐Acting Ocular Injectables: Are We Looking In The Right Direction?

Dang, M., & Shoichet, M. S. (2023) · Advanced Science · doi:10.1002/advs.202306463 · Cited by 17 · see citing works

Moderate‐Affinity Affibodies Modulate the Delivery and Bioactivity of Bone Morphogenetic Protein‐2

Dorogin, J., Hochstatter, H. B., Shepherd, S. O., Svendsen, J. E., Benz, M. A., Powers, A. C., Fear, K. M., Townsend, J. M., Prell, J. S., Hosseinzadeh, P., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300793 · Cited by 16 · see citing works

Engineering of Affibody MoleculesPreprint

Ståhl, S., Lindberg, H., Hjelm, L. C., Löfblom, J., & Leitao, C. D. (2023) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top107760 · Cited by 10 · see citing works

Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

Löfblom, J., Feldwisch, J., Максимилианович, Т. В., Carlsson, J., Ståhl, S., & Frejd, F. Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.014 · Cited by 653 · see citing works

Affibody molecules: therapy and in vivo diagnostic applications

Gräslund, T. (2016) · New Biotechnology · doi:10.1016/j.nbt.2016.06.890

Engineering of Affibody Molecules for Therapy and Diagnostics

Feldwisch, J., & Tolmachev, V. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_7 · Cited by 91 · see citing works

Affibody Molecules in Biotechnological and Medical Applications

Ståhl, S., Gräslund, T., Karlström, A. E., Frejd, F. Y., Nygren, P., & Löfblom, J. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.04.007 · Cited by 385 · see citing works